MedTrace Logo

Open-Label Posterior Juxtascleral Injections of Anecortave Acetate 15mg Dose for Long Term Use in Patients With AMD

NCT00065728 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 111

Last updated 2013-09-16

No results posted yet for this study

Summary

The purpose of this study is to investigate the long-term efficacy and safety of posterior juxtascleral injections of open label Anecortave Acetate 15mg administered every 6 months.

Conditions

  • Macular Degeneration

Interventions

DRUG

Anecortave Acetate (AL-3789) Sterile Suspension, 30 mg/mL

One 0.5 mL injection of 30 mg/mL Anecortave Acetate sterile suspension into the posterior juxtascleral depot at 6 month intervals for 18 months

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Terry Wiernas, PhD · Alcon Research

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-06-30
Primary Completion
2008-10-31
Completion
2008-10-31

Countries

  • United States

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00065728 on ClinicalTrials.gov